(Q52483667)

2 May 2018

title

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors (English)

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

30 October 2022

1 reference

1 reference

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

30 October 2022

author name string

R. J. Motzer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

K. Cooper

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

N. L. Geller

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

D. G. Pfister

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

S. Y. Lin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

D. Bajorin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

H. I. Scher

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

H. Herr

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

W. Fair

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

M. Morse

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1692505

30 October 2022

language of work or name

English

0 references

publication date

1 June 1990

1 reference

2 May 2018

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

30 October 2022

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

30 October 2022

1 reference

2 May 2018

volume

65

1 reference

2 May 2018

issue

11

1 reference

2 May 2018

page(s)

2465-2470

1 reference

2 May 2018

VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors

cites work

1

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

30 October 2022

3

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982)

30 October 2022

5

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Chemotherapy of extragonadal germ cell tumors

30 October 2022

7

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors

30 October 2022

8

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

30 October 2022

9

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

30 October 2022

Cancer Treatment Reports

11

71

197

Motzer

1987

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

30 October 2022

Cancer Treatment Reports

12

67

997

Evans

1983

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion

30 October 2022

13

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Comparing survival distributions: a review for nonstatisticians. II.

30 October 2022

14

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial

30 October 2022

16

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

30 October 2022

17

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors

30 October 2022

18

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies

30 October 2022

21

1 reference

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

https://api.crossref.org/works/10.1002/1097-0142(19900601)65:11%3C2465::AID-CNCR2820651112%3E3.0.CO;2-7

30 October 2022

Identifiers

10.1002/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7

1 reference

2 May 2018

1 reference

2 May 2018